Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P364: The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

O. Prymak*

Medical Clinical Investigational Centre of the Medical Centre LLC Health Clinic, Vinnytsia, Ukraine

P365: Real-world effectiveness of adalimumab in patients with ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

A. Armuzzi*1, C. Taxonera2, J. Panes3, P. Lakatos4, N. Fisseha5, B. Pappalardo5

1Complesso Integrato Columbus-Gemelli University Hospital Foundation, IBD Unit, Rome, Italy, 2Hospital Clínico San Carlos, IdiSSC, Madrid, Spain, 3Hospital Clínic Barcelona, Gastroenterology, Barcelona, Spain, 4Semmelweis University, First Department of Medicine, Budapest, Hungary, 5AbbVie Inc, North Chicago, Illinois, United States

P366: Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysisECCO '16 Amsterdam
Year: 2016
Authors:

G. Losurdo*, A. Iannone, A. Contaldo, E. Ierardi, A. Di Leo, M. Principi

University of Bari, DETO, Bari, Italy

P367: Lower quality of life, more active disease and increased healthcare costs due to non-adherence in inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Severs*1, M.-J. Mangen2, H. H. Fidder1, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

1University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 2University Medical Centre Utrecht, Julius Centre for health sciences and primary care, Utrecht, Netherlands, 3ORBIS medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 4VU medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 5Diaconessenhuis, Gastroenterology and Hepatology, Leiden, Netherlands, 6University Medical Centre Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 7Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University Medical Centre St Radboud, Gastroenterology and Hepatology, Nijmegen, Netherlands, 9Antonius Hospital, Gastroenterology and Hepatology, Nieuwegein, Netherlands, 10Slingeland Hospital, Gastroenterology and Hepatology, Doetinchem, Netherlands, 11Leiden University Medical Centre, Gastroenterology and Hepatology, Leiden, Netherlands, 12University Medical Centre Maastricht, Gastroenterology and Hepatology, Maastricht, Netherlands, 13Academic Medical Centre Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 14Meander Medical Centre, Gastroenterology and Hepatology, Amersfoort, Netherlands, 15Erasmus Medical Centre, Gastroenterology and Hepatology, Rotterdam, Netherlands, 16University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, Netherlands

P368: Risk factors for serious infections in elderly patients receiving infliximab and other Crohn’s disease therapies: TREAT™ registry dataECCO '16 Amsterdam
Year: 2016
Authors:

G. Lichtenstein1, W. Langholff2, B. Feagan*3, R. Cohen4, B. Salzberg5, J. Popp6, R. Nissinen7, W. J. Sandborn8

1University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, Pennsylvania, United States, 2Janssen R & D, LLC, Spring House, Pennsylvania, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 4University of Chicago Medical Centre, Department of Gastroenterology, Chicago, Illinois, United States, 5Atlanta Gastroenterology Specialists PC, Atlanta, Georgia, United States, 6Janssen Pharmaceuticals, Horsham, Pennsylvania, United States, 7Janssen Biologics BV, Leiden, Netherlands, 8University of California San Diego, Division of Gastroenterology, La Jolla, California, United States

P369: Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

J. Panés*1, C. Su2, A. Marren2, D. Yu2, D. Woodworth2, H. Zhang2, P. Healey3

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Pfizer Inc, Collegeville, United States, 3Pfizer Inc, Groton, United States

P370: Treatment patterns in a managed care project with inflammatory bowel disease patients in Germany: CEDnetz studyECCO '16 Amsterdam
Year: 2016
Authors:

B. Bokemeyer*1, J. Langbrandtner2, P. Jessen3, J. Büning4, S. Schreiber5, H. Raspe2, A. Hüppe2

1Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany, 2Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie, Lübeck, Germany, 3Gastroenterology Practice, Gastroenterology, Altenholz, Germany, 4University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany, 5Christian-Albrechts-Universität, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany

P371: Concentrations of 6-thioguanine nucleotide correlate with both infliximab and adalimumab levels in patients with inflammatory bowel disease on combination therapyECCO '16 Amsterdam
Year: 2016
Authors:

O. Kelly*, A. Trajkovski, A. Weizman, G. Nguyen, A. H. Steinhart, M. Silverberg, K. Croitoru

Mount Sinai Hospital, Centre for Inflammatory Bowel Disease. Suite 437, Toronto, Canada

P372: A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis*ECCO '16 Amsterdam
Year: 2016
Authors:

H. H. Radeke*1, 2, J. Stein1, 3, W. Kruis4

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2Pharmazentrum Frankfurt, Hospital of the Goethe University Frankfurt, Frankfurt/Main, Germany, 3DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 4LKP, Evangelisches Krankenhaus Kalk, Cologne, Germany

P373: Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

M. Ribeiro Feitosa1, R. S. Parra*1, O. Feres Filho2, J. J. Ribeiro da Rocha1, O. Féres1

1University of Sao Paulo, Surgery and Anatomy, Ribeirao Preto SP, Brazil, 2University of Sao Paulo, Department of Surgery and Anatomy, Ribeirao Preto SP, Brazil

P374: Efficacy of a micronised, dispersible ferric pyrophosphate in children with anaemia associated with inflammatory bowel disease.ECCO '16 Amsterdam
Year: 2016
Authors:

A. Wegner*1, G. Mierzwa2, S. Wiecek3, A. Korlatowicz- Bilar4, M. Dadalski5, B. Korczowski6, J. Kierkus7

1Public Children’s Clinical Hospital, Warszawa, Poland, 2Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, Chair of Vascular and Internal Diseases,, Bydgoszcz, Poland, 3Medical University of Silesia, Department of Paediatrics,, Katowice, Poland, 4Children’s Hospital, Department of Paediatrics, Gastroenterology and Rheumatology, Szczecin, Poland, 5Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Eating Disorders,, Warsaw, Poland, 6University of Rzeszów, Department of Paediatrics and paediatric Gastroenterology State Hospital No 2, Rzeszów, Poland, 7Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Eating Disorders, Warsaw, Poland

P375: Long-term outcomes after primary infliximab treatment failure in patients with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

S. Buhl*, C. Steenholdt, M. Borghede, M. Rasmussen, J. Brynskov, O. Ø. Thomsen, M.A. Ainsworth

Copenhagen University Hospital, Herlev, Department of Gastroenterology, Herlev, Denmark

P376: Therapy refractory ulcerative colitis patients may benefit from appendectomy: early result from the PASSION studyECCO '16 Amsterdam
Year: 2016
Authors:

S. Sahami*1, C. Buskens1, D. Winter2, S. Martin2, P. Tanis1, G. van den Brink3, M. Löwenberg3, G. Cullen4, H. Mulcahy4, G. Doherty4, C. Ponsioen3, G. D’Haens3, W. Bemelman1

1Academic Medical Centre, Surgery, Amsterdam, Netherlands, 2St. Vincent’s University Hospital, Surgery, Dublin, Ireland, 3Academic Medical Centre, Gastroenterology & Hepatology, Amsterdam, Netherlands, 4St. Vincent’s University Hospital, Gastroenterology & Hepatology, Dublin, Ireland

P377: Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

H. Imaeda*, Y. Morita, T. Fujimoto, K. Takahashi, M. Shioya, A. Nishida, O. Inatomi, S. Bamba, M. Sasaki, T. Tsujikawa, M. Sugimoto, A. Andoh

Shiga University of Medical Science, Department of Medicine, Otsu, Japan

P378: The outcomes of a clinical care pathway for inflammatory bowel disease surgeryECCO '16 Amsterdam
Year: 2016
Authors:

A. Platt*1, A. Lightner2, R. Jacobs1, D. Sagar1, W. van Deen1, T. Hommes1, S. Reardon3, J. Sack3, D. Hommes1

1UCLA Centre for Inflammatory Bowel Diseases, Department of Digestive Diseases, Los Angeles, California, United States, 2Mayo Clinic College of Medicine, Division of Colon and Rectal Surgery, Rochester, Minnesota, United States, 3UCLA, Department of Colorectal Surgery, Los Angeles, California, United States

P379: Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulationECCO '16 Amsterdam
Year: 2016
Authors:

M. S. Prüß*, A. Farmer, B. Siegmund

Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany

P380: Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s diseaseECCO '16 Amsterdam
Year: 2016
Authors:

E. Szymanska*1, M. Dadalski2, S. Szymanska3, W. Grajkowska3, M. Pronicki3, K. Jaroslaw2

1Children’s Memorial Health Institute, Department of Paediatrics, Nutrition and Metabolic Disorders, Warsaw, Poland, 2Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland, 3Children’s Memorial Heath Institute, Department of Pathology, Warsaw, Poland

P381: An observational study of adverse events of patients with inflammatory bowel disease receiving parenteral ironECCO '16 Amsterdam
Year: 2016
Authors:

A. Wilson*, E. Murray, G. B. Turner

Belfast Trust, Belfast, United Kingdom

P382: Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel diseaseECCO '16 Amsterdam
Year: 2016
Authors:

R. Muhammed*, L. Whyte, S. Protheroe, R. Bremner, W. Haller, T. Wong

Birmingham Children’s Hospital, Gastroenterology, Birmingham, United Kingdom

P383: Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory ulcerative colitisECCO '16 Amsterdam
Year: 2016
Authors:

S. Motoya*, M. Miyakawa, M. Nasuno, H. Tanaka

Sapporo-Kosei General Hospital, IBD Centre, Sapporo, HOKKAIDO, Japan